A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
← catalyst calendarNCT07652658 · readout in 757 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
359estimated
Sites
190
Countries
Argentina, Australia, Bulgaria +19
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-11 | actual | When the study began enrolling |
| Primary completion | 2028-09-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-09-14 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Idiopathic Pulmonary Fibrosis (IPF)
Interventions
- Other: Placebo for AZD8965
- Drug: AZD8965 low dose
- Drug: AZD8965 medium dose
- Drug: AZD8965 high dose
Primary outcome
what the primary-completion date above is the date OFTo evaluate the clinical efficacy of AZD8965 compared with placebo on the absolute change from baseline in FVC in mL at Week 24
measured at Week 24
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed